Acyclomirtazapine alcohol
正在补全数据,稍后刷新页面可查看最新内容
61337-89-1CN1CCN(c2ncccc2CO)C(c2ccccc2)C1PYZPABZGIRHQTA-UHFFFAOYSA-N61337-89-1DTXSID901036336安全信息仅供参考,不能替代供应商安全技术说明书(SDS)、适用法规与专业评估。
Danger
H302+H312+H332 (85%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]
P233, P260, P261, P264, P264+P265, P270, P271, P272, P273, P280, P284, P301+P317, P302+P352, P304+P340, P305+P354+P338, P317, P321, P330, P333+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 20 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
用途用作抗抑郁药米氮平中间体
生产方法以2-(4-甲基-2-苯基-1-哌嗪)-3-吡啶甲酸为原料合成2-(4-甲基-2-苯基-1-哌嗪基)-3-吡啶甲醇的一般步骤:向配备有搅拌叶片和温度计的2L四颈烧瓶中加入1618mL(1618mmol)1mol/L氢化铝锂的四氢呋喃溶液。随后,将120g(404mmol)的2-(4-甲基-2-苯基-1-哌嗪)-3-吡啶甲酸溶解于1800mL四氢呋喃中,保持反应温度在约25℃,并在30分钟内缓慢滴加该溶液至反应瓶中。滴加完毕后,继续在25℃下搅拌反应混合物3小时。反应完成后,缓慢加入70mL水,同时用水浴冷却反应溶液,并搅拌混合物。之后,分离有机层和水层,有机层依次用70mL 15wt%氢氧化钠水溶液和200mL水洗涤,分离后得到有机层。将有机层减压浓缩,得到2-(4-甲基-2-苯基-1-哌嗪基)-3-吡啶甲醇的粗产物。向粗产物中加入840mL乙酸异丙酯,加热至60℃使其完全溶解,然后在内部温度不低于50℃的条件下,缓慢滴加840mL庚烷。将所得溶液冷却至5℃,并在该温度下老化浆料2小时。随后,通过真空过滤收集固体,并用60mL乙酸异丙酯和60mL庚烷的混合溶液洗涤过滤得到的晶体。最后,将白色晶体在40℃下减压干燥5小时,得到102g(363mmol,产率:89%)的2-(4-甲基-2-苯基-1-哌嗪基)-3-吡啶甲醇,纯度为99.53%,水含量为320ppm。参考文献:[1] Patent: US2002/35255, 2002, A1[2] Organic Preparations and Procedures International, 2007, vol. 39, # 4, p. 399 - 402[3] Patent: JP2017/39659, 2017, A. Location in patent: Paragraph 0048-0049[4] Patent: JP2017/88565, 2017, A. Location in patent: Paragraph 0060; 0061[5] Patent: JP2017/88564, 2017, A. Location in patent: Paragraph 0056; 0057